Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, despite mounting anxiety over that coronavirus, because that oh-so-familiar routine of meetings, deadlines, and the like has predictably returned. To cope, yes, we have fired up the coffee kettle and we are brewing cups of stimulation. Our choice today is peppermint mocha, for those of you who are curious. Meanwhile, here are a few items of interest to help you get going. Hope you survive the day and do keep in touch.

AbbVie (ABBV) says China is testing one of its HIV medicines as a treatment for symptoms of the new coronavirus that is rapidly spreading, Reuters writes. Aluvia, which is also known as Kaletra, is a combination of lopinavir and ritonavir. In guidance published last week, the Chinese government said there is no effective anti-virus medicine but suggested taking two Aluvia pills and inhaling a dose of nebulized alpha-interferon twice a day.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy